Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Net Cash Flow (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Net Cash Flow for 8 consecutive years, with -$13.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 506.06% to -$13.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$50.1 million, a 5449.94% decrease, with the full-year FY2024 number at -$8.2 million, up 88.74% from a year prior.
  • Net Cash Flow was -$13.6 million for Q3 2025 at Precision Biosciences, up from -$15.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $103.7 million in Q1 2021 to a low of -$31.4 million in Q1 2023.
  • A 5-year average of -$978210.5 and a median of -$13.6 million in 2025 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: surged 488.26% in 2021, then crashed 506.06% in 2025.
  • Precision Biosciences' Net Cash Flow stood at -$16.8 million in 2021, then tumbled by 33.72% to -$22.5 million in 2022, then surged by 75.29% to -$5.6 million in 2023, then plummeted by 131.59% to -$12.9 million in 2024, then dropped by 5.71% to -$13.6 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Net Cash Flow are -$13.6 million (Q3 2025), -$15.0 million (Q2 2025), and -$8.7 million (Q1 2025).